About
About Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research, development, production, and sale of pharmaceutical raw materials and preparations in China and internationally. The company offers generics for oncology, critical care, IVF, and diabetes; and standard heparin preparations and low molecular weight heparin preparations, including enoxaparin sodium injections, dalteparin sodium injection, and nadroparin calcium injection. It also provides non-heparin sterile injections, such as adalimumine injection, paclitaxel injection, liraglutide injection, daptomycin for injection, pantoprazole sodium for injection, reganoxone injection, leucovorin calcium for injection, bivalirudin for injection, micafungin for injection, ducalciferol injection, fondaparinux sodium injection, and cisatracurium besylate injection. In addition, the company offers process development and preparation, process optimization, registration and validation approval, and manufacturing, as well as customized research and development, and manufacturing for commercialization. Its injection products are used in anticoagulation, anti-tumor, and cardiovascular disease areas, surgical anesthesia, antibacterial infection, and contrast imaging. The company was founded in 2000 and is based in Nanjing, China.
Research context
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd appears in PyInvesting’s Shanghai Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 1.6% below its 200 day moving average.
From a valuation standpoint, the stock is 35.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 13.0.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd's total revenue rose by 17.1% to $763M since the same quarter in the previous year.
Its net income has increased by 28.4% to $205M since the same quarter in the previous year.
Finally, its free cash flow grew by 13.5% to $-305M since the same quarter in the previous year.
Based on the above factors, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd gets an overall score of 3/5.